Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.49 Insider Own44.80% Shs Outstand39.56M Perf Week-11.30%
Market Cap5.25M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float21.84M Perf Month-15.48%
Income-15.47M PEG- EPS next Q- Inst Own25.00% Short Float1.54% Perf Quarter-72.35%
Sales0.00M P/S- EPS this Y- Inst Trans-27.01% Short Ratio0.60 Perf Half Y-82.99%
Book/sh-0.13 P/B- EPS next Y- ROA-714.74% Short Interest0.34M Perf Year-91.21%
Cash/sh0.04 P/C3.18 EPS next 5Y- ROE- 52W Range0.13 - 1.55 Perf YTD-77.50%
Dividend Est.- P/FCF- EPS past 5Y-16.06% ROI- 52W High-91.44% Beta-0.68
Dividend TTM- Quick Ratio0.58 Sales past 5Y- Gross Margin- 52W Low1.22% ATR (14)0.03
Dividend Ex-Date- Current Ratio0.58 EPS Y/Y TTM52.59% Oper. Margin0.00% RSI (14)25.16 Volatility10.14% 12.85%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q63.33% Payout- Rel Volume0.13 Prev Close0.13
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume563.85K Price0.13
SMA20-15.12% SMA50-54.38% SMA200-77.60% Trades Volume73,626 Change0.00%
Apr-19-24 05:00PM
Mar-22-24 04:30PM
Mar-20-24 01:40PM
Mar-14-24 08:00AM
07:00AM Loading…
Mar-11-24 07:00AM
Feb-23-24 07:30AM
Jan-12-24 04:30PM
Dec-29-23 04:30PM
Dec-04-23 09:06AM
Dec-01-23 07:30AM
Nov-28-23 07:30AM
Nov-27-23 08:30AM
Nov-16-23 08:00AM
04:30PM Loading…
Oct-25-23 04:30PM
Oct-19-23 05:00PM
Oct-12-23 09:40AM
Aug-28-23 07:30AM
Jul-03-23 07:00AM
Jun-30-23 04:05PM
Jun-19-23 07:30AM
Jun-15-23 08:30AM
Jun-14-23 07:30AM
May-08-23 08:30AM
May-04-23 08:30AM
May-02-23 08:45AM
08:50AM Loading…
Apr-25-23 08:50AM
Mar-27-23 08:30AM
Mar-01-23 08:30AM
Jan-30-23 08:30AM
Jan-25-23 08:30AM
Jan-23-23 08:30AM
Jan-12-23 08:30AM
Jan-11-23 08:30AM
Jan-10-23 08:30AM
Dec-22-22 08:30AM
Dec-20-22 09:05AM
Dec-14-22 08:30AM
Dec-07-22 08:25AM
Dec-01-22 08:00AM
Nov-23-22 08:30AM
Nov-14-22 08:30AM
Nov-07-22 08:45AM
Nov-02-22 10:40AM
Oct-05-22 04:30PM
Oct-03-22 08:30AM
Sep-27-22 12:02PM
Sep-19-22 08:00AM
Sep-08-22 08:00AM
Jul-28-22 08:30AM
Jul-21-22 08:30AM
Jun-10-22 04:30PM
Jun-06-22 08:30AM
Jun-02-22 08:30AM
May-04-22 09:00AM
Apr-26-22 06:45PM
Apr-22-22 12:00PM
Apr-13-22 08:30AM
Apr-01-22 05:25PM
Mar-31-22 08:15AM
Mar-28-22 08:30AM
Mar-25-22 08:30AM
Mar-16-22 01:49PM
Feb-25-22 09:30AM
Feb-11-22 08:30AM
Feb-07-22 08:46AM
Jan-12-22 08:15AM
Jan-04-22 08:15AM
Nov-30-21 08:30AM
Nov-01-21 08:15AM
Oct-20-21 08:48AM
Oct-14-21 08:30AM
Oct-04-21 04:30PM
Sep-30-21 11:55AM
Sep-28-21 08:30AM
Sep-24-21 08:15AM
Sep-14-21 08:30AM
Sep-08-21 08:00AM
Aug-19-21 11:44AM
Aug-05-21 08:30AM
Jul-30-21 09:08AM
Jul-19-21 08:30AM
Jul-15-21 08:15AM
Jul-09-21 08:15AM
Jul-08-21 11:20AM
Jun-23-21 09:35AM
Jun-15-21 06:41AM
Jun-02-21 08:00AM
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.